Jagsonpal acquires 69.77% stake in Aequitas Healthcare, makes it subsidiary

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹237.90

prior close

₹232.39

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%+1.2% vs market

Pharmaceuticals peers, median of 165sector-0.4%+0.9% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.3

10m

+2.2

15m

+2.7

30m

+2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5-0.7+1.2-0.4+0.9

Next day

-3.8-2.7-1.1-1.3-2.5

-2.6-0.8-1.8-0.6-2.0

-2.1+0.5-2.6+0.1-2.1

-3.5+0.7-4.1+0.5-4.0

-5.3-0.3-5.0+0.2-5.5

-5.2-0.2-5.1+0.6-5.9

15d

-5.8-1.7-4.1-1.7-4.1

-2.7+2.7-5.4-1.0-1.7

+0.8+4.8-4.0+1.9-1.1

-1.2+3.2-4.4+0.5-1.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals has acquired a 69.77% equity stake in Aequitas Healthcare Private Limited, making it a subsidiary. The company had earlier proposed to acquire an 85% stake, and this filing confirms the first part of the deal has been completed. The remaining stake purchase is still pending. The update was disclosed under SEBI LODR Regulation 30.

Likely market impact

Aequitas becomes a subsidiary, expanding Jagsonpal's healthcare presence. Consolidated results will include Aequitas from this date onward.